Analysis of the impact of radiotherapy on long-term treatment results in patients with malignant salivary gland tumors

Cover Page

Cite item

Full Text

Abstract

Objective: to investigate the efficiency of radiotherapy for malignant salivary gland tumors and to reveal prognostic factors influencing overall and relapse-free survival rates in this patient group.

Materials and methods. The retrospective and prospective data of 111 patients with malignant salivary gland tumors were analyzed. All the examinees received preoperative radiotherapy to the primary focus and, if need be, regional metastatic areas; the cumulative focal dose was 40–65 (56.0 ± 8.9) Gy. In the following step, the patients were surgically treated. They were divided into 2 groups according to the degree of therapeutic pathomorphism: 1) Degree 0–III (91.9 %) and 2) Degree IV (8.1 %).

Results. Five- and ten-year overall survival rates were 60.1 ± 5.1 and 50.4 ± 5.7 % and 7.5 ± 11,69 and 87.5 ± 11.69 % (unachieved median) in Groups 1 and 2, respectively (p = 0.04); relapse-free survival rates were 53.6 ± 5.1 and 41.33 ± 5.5 % in Group 1 and 88.8 ± 10.4 and 88.8 ± 10.4 % in Group 2 (unachieved median) (р = 0.015). Cox multivariate regression analysis showed that the significant independent signs for overall survival were the pathomorphological characteristics of a tumor (risk ratio (RR) = 1.933; p = 0.010), process location (RR = 0.705; р = 0.010), and tumor grade (RR = 1.825; р = 0.010); those for relapse-free survival were the pathomorphological characteristics of a tumor (RR = 2.177; р = 0.001), regional lymph node metastases (RR = 1.543; р = 0.013), tumor localization (RR = 0.700; р = 0.014), effect of radiotherapy (RR = 1.767; р = 0.042), and tumor grade (RR = 1.754; р = 0.005).

About the authors

V. T. Vayradyan

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Author for correspondence.
Email: v_violetta@list.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

A. M. Mudunov

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

R. I. Azizyan

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

I. A. Zaderenko

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

S. B. Alieva

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

N. V. Rurua

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

T. T. Kondrat’eva

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

V. D. Ermilova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.